Navigation Links
Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology
Date:10/2/2008

OXFORD, England, October 2 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on the fields of allergy and critical care, today announced the start of a further phase II clinical study of its ToleroMune(R) technology in the field of cat allergy. The trial builds on positive results achieved in an earlier phase II study, which demonstrated the potential clinical benefits of the ToleroMune approach to allergy desensitization.

In the previous phase II clinical trial, patients experienced substantially reduced reactions to cat allergens after a single administration of ToleroMune therapy. The current study builds on this work, and will explore different 4-dose treatment regimens, which are designed to enhance the patients' response and determine the best therapeutic approach. During the study, patients will receive a controlled dose of cat allergen in an environmental exposure chamber both before and after treatment, and will then complete a questionnaire to score their allergic rhinitis symptoms. This will allow investigators to evaluate the impact of the different treatment regimes. The double-blind, randomized, placebo-controlled trial will include a total of 120 volunteers with confirmed cat allergies. The study, which is already underway in Canada, is progressing well with approximately 20% of patients enrolled for screening so far.

"This study is of great importance for Circassia as it is designed to define the most effective treatment regime for our ToleroMune allergy products, and in particular for the phase III studies of our cat-allergy therapy that are planned to begin in the second half of 2009," said Steve Harris, Circassia's CEO. "The results of our trials to date show that our ToleroMune approach offers patients substantial potential benefits. Conventional allergy treatments either address symptoms only or require many doses over a period of months under specialist supervision because they can result in serio
'/>"/>

SOURCE Circassia Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Circassia Achieves Successful Phase II Clinical Results With Toleromune(R) Anti-Allergy Technology
2. Baxter Initiates Phase III Trial for the Treatment of Alzheimers Disease
3. S*BIO Initiates U.S. Phase I Clinical Trials of Oral JAK2 Inhibitor SB1518 for the Treatment of Hematological Malignancies
4. Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA
5. QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome
6. Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections
7. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
8. Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing
9. Enobia Pharma Initiates Clinical Testing of Enzyme Replacement Therapy to Treat Hypophosphatasia
10. Isis Initiates Clinical Trial of CRP Drug
11. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014 According to ... "Endoscopy Devices Market (Endoscopes, Endoscopic Operative Devices, and Visualization ... and Forecast, 2013-2019" the global endoscopy devices market was ... expected to grow at a CAGR of 6.8% from ... USD 36.9 billion in 2019. Browse the ...
(Date:7/11/2014)... 2014 Neurelis, Inc. ("Neurelis") today announced an ... option held by Biotie to purchase Neurelis, clearing the ... (intranasal diazepam) for pediatric and adult epilepsy patients who ... year, Biotie has advanced the development program for NRL-1 ... clinical work required for NDA submission to the FDA.  ...
(Date:7/10/2014)... 2014  Breg, Inc., a premier provider of ... FreeRunner™ knee brace with new innovations to help ... return to active lifestyles.  FreeRunner,s patent-pending design acts ... support when patients need it most, and the ... Patellofemoral issues are the most common cause ...
Breaking Medicine Technology:Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2
... study results also demonstrate the longest duration of consistently ... levels shown by a cervical cancer vaccine, TAMPA, ... GSK ) cervical cancer candidate vaccine,CERVARIX(R) provides significant ... human papillomavirus types for nearly six and a half,years, ...
... SOUTH SAN FRANCISCO, Calif., March 10 ... clinical-stage biopharmaceutical,company focused on the discovery, development ... positive interim data,from the company,s ongoing Phase ... SNS-595, in platinum-resistant ovarian cancer patients., ...
Cached Medicine Technology:GSK Cervical Cancer Candidate Vaccine CERVARIX (R) Demonstrates Long-Term Protection for More Than Six Years 2GSK Cervical Cancer Candidate Vaccine CERVARIX (R) Demonstrates Long-Term Protection for More Than Six Years 3GSK Cervical Cancer Candidate Vaccine CERVARIX (R) Demonstrates Long-Term Protection for More Than Six Years 4GSK Cervical Cancer Candidate Vaccine CERVARIX (R) Demonstrates Long-Term Protection for More Than Six Years 5GSK Cervical Cancer Candidate Vaccine CERVARIX (R) Demonstrates Long-Term Protection for More Than Six Years 6Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer 2Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer 3Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer 4Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer 5
(Date:7/11/2014)... The Corn Farming industry experienced ... the heels of fresh biofuel demand. The Federal Renewable ... larger share of their farmland to cultivating high-value corn ... the mixing of 5.0% renewable content in gasoline across ... States created a key export market for Canadian corn, ...
(Date:7/11/2014)... CA (PRWEB) July 11, 2014 Ticket ... Bryan Tickets at the Sleep Train Amphitheatre in Wheatland, ... venues that can compare to what the Sleep Train Amphitheatre ... musical events and special attractions over the course of its ... 16th, the Sleep Train Amphitheatre in Wheatland (Sacramento metro area) ...
(Date:7/11/2014)... are insoluble colorants, which usually consist of inorganic compounds. ... and coloring. These are water and oil insoluble natural ... as paper, paints, plastics, and concrete. Binders are used ... to the substance. Some examples of pigments are titanium ... coloring action of pigments is due to the scattering ...
(Date:7/11/2014)... York, NY (PRWEB) July 11, 2014 ... dramatic increase in men seeking cosmetic surgery and hair ... year. With such an expansive range of medical tourism ... exceptional plastic surgery costs and achieve the ... to be renowned as the top name in the ...
(Date:7/11/2014)... prescribed exercise as medicine, according to a QUT ... is essential to reducing the risk of death ... QUT,s Institute of Health and Biomedical Innovation, said ... and mental health, health professionals should be prescribing ... Anderson and QUT,s Dr Charlotte Seib co-authored a ...
Breaking Medicine News(10 mins):Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 2Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 3Health News:Luke Bryan Tickets Sleep Train Amphitheatre in Wheatland, CA (Sacramento): Ticket Down has Slashed Ticket Prices on Luke Bryan in Wheatland at Sleep Train 2Health News:Luke Bryan Tickets Sleep Train Amphitheatre in Wheatland, CA (Sacramento): Ticket Down has Slashed Ticket Prices on Luke Bryan in Wheatland at Sleep Train 3Health News:Americas Pigments Market Worth 1,099 Thousand MT by 2018 - New Report by MicroMarket Monitor 2Health News:Americas Pigments Market Worth 1,099 Thousand MT by 2018 - New Report by MicroMarket Monitor 3Health News:VisitandCare.com Reports Increase in Cosmetic and Hair Transplant Procedures for Men 2Health News:VisitandCare.com Reports Increase in Cosmetic and Hair Transplant Procedures for Men 3Health News:Exercise is the best medicine: QUT study 2
... (Aug. 25, 2009) The Henry M. Jackson Foundation ... three promising Uniformed Services University of the Health Sciences ... year. The program, established in 1988, is comprised of ... Hemming Fellowship. Each fellow receives a stipend and travel ...
... The University of Nottingham and Health Protection Agency East Midlands ... after being commissioned as part of the government,s response to ... long someone is contagious for and advise on a ,safe ... by Professor Jonathan Nguyen Van Tam of the University of ...
... YORK, August 25, 2009 -- Charleen T. Chu, MD, ... David M. Sabatini, MD, PhD, associate professor, Massachusetts Institute ... in Aging Research. Sponsored by The Ellison Medical ... scientists whose research has great potential in advancing understanding ...
... , , SAN ... of Bone and Joint Surgery demonstrates that use of ... effective than both DuraPrep and povidone-iodine at eliminating overall bacteria ... chlorhexidine gluconate and 70 percent isopropyl alcohol), only seven percent ...
... , , , , ... Judd is speaking up for those struggling with chronic pain -- a ... combined. Judd is lending her voice to the national education program ... instpain.com ) to raise awareness about the urgent need to ...
... SAN RAFAEL, Calif., Aug. 25 TBI/Tissue Banks International, one of ... Services (NWTS), a Puget Sound Blood Center program, have entered into ... surgeons and hospitals that rely on them for transplantable tissue. ... immediately, allows TBI to distribute tissue recovered and processed by NWTS ...
Cached Medicine News:Health News:Henry M. Jackson Foundation names fellowship award winners 2Health News:Nottingham scientists commissioned for urgent swine flu research 2Health News:Ellison Medical Foundation awards more than $1 million to mid-career scientists 2Health News:New Data Show ChloraPrep(R) Significantly More Effective Than DuraPrep(TM) and Povidone-Iodine in Eliminating Bacteria From Skin Prior to Shoulder Surgery 2Health News:New Data Show ChloraPrep(R) Significantly More Effective Than DuraPrep(TM) and Povidone-Iodine in Eliminating Bacteria From Skin Prior to Shoulder Surgery 3Health News:New Data Show ChloraPrep(R) Significantly More Effective Than DuraPrep(TM) and Povidone-Iodine in Eliminating Bacteria From Skin Prior to Shoulder Surgery 4Health News:New Data Show ChloraPrep(R) Significantly More Effective Than DuraPrep(TM) and Povidone-Iodine in Eliminating Bacteria From Skin Prior to Shoulder Surgery 5Health News:Country Legend Naomi Judd Joins 'Partners Against Pain' 2Health News:Country Legend Naomi Judd Joins 'Partners Against Pain' 3Health News:TBI/Tissue Banks International and Northwest Tissue Services Announce Collaborative Distribution Agreement 2
... is an effective angina relief ... poor targets. Because it is ... the CO2 Heart Laser 2 ... timely operative decisions to revascularize ...
Ultrasensitive TSH EIA Thyroid Function 025-BC-1003...
TG (Ab) RIA Thyroid Function 014-HD 27.1 Thyroglobulin...
... The anti-TG test kit is a solid ... format. It is designed for the quantitative ... (TG) in serum or plasma. The microplate ... Calibrators, controls and patient samples are pipetted ...
Medicine Products: